logo

For the Inventor, By the Inventor

Tübingen, Germany

Curevac Ag

Calculating rank
USPTO Granted Patents = 97

% Expired Patents = 19.6



Trademarks = 12

Forward Citations = 3,021

Loading Chart...
Loading Chart...

61 inventors (with patents filed for the assignee):

goldMedal Jochen Probst (29 out of 37 patents)

silverMedal Andreas Thess (25 out of 67 patents)

bronzeMedal Thomas Schlake (22 out of 33 patents)

4.  Karl-Josef Kallen (20 out of 29 patents)

5.  Mariola Fotin-Mleczek (19 out of 28 patents)

6.  Ingmar Hoerr (16 out of 22 patents)

7.  Benjamin Petsch (14 out of 46 patents)

8.  Thomas Kramps (12 out of 26 patents)

9.  Patrick Baumhof (12 out of 22 patents)

10.  Margit Schnee (11 out of 21 patents)

11.  Steve Pascolo (11 out of 24 patents)

12.  Florian Von Der Mülbe (10 out of 20 patents)

13.  Tilmann Roos (7 out of 20 patents)

14.  Benyamin Yazdan Panah (7 out of 16 patents)

15.  Thomas Ketterer (7 out of 25 patents)


Core Competencies:
mRNA
Vaccines
Nucleic Acids
RNA Therapeutics
Immunostimulation
Protein Expression
Vaccine Composition
Long-Chain RNA
Combination Vaccines
Antigen Presentation
RNA-Encoded Proteins
Adjuvants

97 patents:

1. 12528855 - KRAS VARIANT MRNA MOLECULES (2026-01-20),
2. 11534405 - Dry powder composition comprising long-chain RNA (2022-12-27),
3. 11478552 - Hybrid carriers for nucleic acid cargo (2022-10-25),
4. 11471525 - Coronavirus vaccine (2022-10-18),
5. 11464847 - Lassa virus vaccine (2022-10-11),
6. 11464836 - RNA for treatment or prophylaxis of a liver disease (2022-10-11),
7. 11458195 - Combination of vaccination and inhibition of the PD-1 pathway (2022-10-04),
8. 11458193 - Combination of vaccination and inhibition of MHC class I restricted antigen presentation (2022-10-04),
9. 11433027 - Dry powder composition comprising long-chain RNA (2022-09-06),
10. 11421038 - RNA-coded antibody (2022-08-23),
11. 11413346 - Rotavirus vaccines (2022-08-16),
12. 11384375 - Immobilized poly(n)polymerase (2022-07-12),
13. 11369694 - Rabies vaccine (2022-06-28),
14. 11369691 - Pharmaceutical composition containing a stabilised mRNA optimised for translation in its coding regions (2022-06-28),
15. 11345920 - Artificial nucleic acid molecules for improved protein expression (2022-05-31),
Company Overview
CureVac AG, based in Tübingen, Germany, is a pioneering biotechnology company specializing in RNA therapeutics. The organization focuses on the development and manufacturing of mRNA-based vaccines and therapies, leveraging its expertise in nucleic acids to address various medical challenges. CureVac's innovative approach encompasses immunostimulation and protein expression, aiming to enhance vaccine composition and efficacy. With a commitment to advancing RNA technology, CureVac is at the forefront of transforming therapeutic strategies in infectious diseases and beyond.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

Curevac Ag USPTO Patent Assignee Logo
97 Patents

#3 in Tübingen

#607 in Germany

#7,996 in the World

Tübingen, DE
Tübingen, Germany

Curevac Ag

Forward Citations = 3,021

61 inventors:

goldMedal Jochen Probst (29 out of 37 patents)

silverMedal Andreas Thess (25 out of 67 patents)

bronzeMedal Thomas Schlake (22 out of 33 patents)

4.  Karl-Josef Kallen (20 out of 29 patents)

5.  Mariola Fotin-Mleczek (19 out of 28 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Curevac Ag. Retrieved from https://idiyas.com/company/curevac-ag

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…